Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson Progress
0% Complete
Diagnostic Evaluation and Risk Stratification in Febrile Neutropenia

Diagnostic Evaluation and Risk Stratification in Febrile Neutropenia

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Objective

Apply a structured approach to history, exam, diagnostics and risk scoring to guide initial management of febrile neutropenia (FN).

1. Initial Clinical Assessment

Early recognition of febrile neutropenia (FN) and prompt initiation of broad-spectrum antibiotics (within 60 minutes) are critical interventions that save lives. Standardized definitions are used to trigger the diagnostic and therapeutic cascade.

A. Fever Definitions and Timing Goals

  • Fever: A single oral temperature ≥ 38.3 °C (101 °F) or a sustained temperature ≥ 38.0 °C (100.4 °F) for at least one hour.
  • Neutropenia: An absolute neutrophil count (ANC) < 500 cells/µL, or an ANC expected to fall below 500 cells/µL within the next 48 hours.
  • The 60-Minute Rule: The goal is to obtain all necessary cultures and administer the first dose of a broad-spectrum anti-pseudomonal β-lactam antibiotic within 60 minutes of the patient’s presentation or fever documentation.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Every Minute Counts

Delays in antibiotic administration beyond the 60-minute window are directly associated with an increased risk of progression to septic shock and higher mortality. Documenting “time zero” (fever onset) and time of antibiotic administration is a key quality metric.

B. Comprehensive History

  • Chemotherapy Details: Identify specific agents, dosing, and the expected timing of the nadir. High-dose cytarabine and platinum-based regimens carry a high risk for profound, prolonged neutropenia.
  • Comorbidities: Note conditions like diabetes, COPD, and renal or hepatic dysfunction that can impair host defenses or affect drug choice. A history of mucositis or prior colonization with resistant organisms (e.g., MRSA, VRE) is critical.
  • Social Determinants: Assess the patient’s proximity to the medical facility, transportation access, and the reliability of home support. These factors are essential for determining candidacy for outpatient management.

C. Focused Physical Exam

  • Mucosal Surfaces: Carefully inspect the oral cavity and perianal region for ulcers, fissures, or severe mucositis, which are common portals of entry for infection.
  • Indwelling Catheters: Examine all central line exit sites and tunnels for erythema, tenderness, or purulence, which suggest a line-related infection.
  • Lungs: Pulmonary findings like crackles may be subtle or absent in neutropenic patients due to a blunted inflammatory response.
  • Hemodynamics: Hypotension, tachycardia, and altered mental status are red flags for sepsis, warranting immediate fluid resuscitation, consideration of vasopressors, and an ICU consultation.
Clinical Vignette: A 63-year-old with AML on induction chemotherapy presents with a temperature of 38.6 °C and an ANC < 100 cells/µL. He has no chills but is tachycardic. Blood cultures are drawn, and cefepime is started at the 45-minute mark.

2. Laboratory and Microbiological Workup

The laboratory evaluation aims to confirm neutropenia, assess for end-organ dysfunction, and identify the causative pathogen. All cultures should be obtained before the first antibiotic dose is administered.

A. Hematologic and Metabolic Panels

  • Complete Blood Count (CBC): Confirms the severity of neutropenia (mild: 500–1,000; severe: < 500; profound: < 100 cells/µL). A peripheral smear can reveal a left shift or toxic granulations, indicating a marrow response.
  • Comprehensive Metabolic Panel (CMP): Assesses renal (Creatinine, BUN) and hepatic (AST, ALT, Bilirubin) function to guide antimicrobial dosing and identify organ injury.
  • Serum Lactate: A level ≥ 2 mmol/L suggests tissue hypoperfusion, even in normotensive patients. Serial measurements are useful for monitoring the response to resuscitation.

B. Microbiological Studies

  • Blood Cultures: Obtain at least two sets (one aerobic, one anaerobic bottle per set). One set should be drawn from a peripheral vein, and one set from each lumen of any indwelling central venous catheter.
  • Site-Specific Cultures: Collect urine, sputum, or wound cultures if localizing signs or symptoms are present.
  • Biomarkers: Procalcitonin has moderate sensitivity and specificity for bacteremia in FN but should not delay empiric therapy; its primary utility may be in guiding de-escalation. C-reactive protein (CRP) is nonspecific and often lags behind clinical events.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Differential Time to Positivity (DTP)

Accurately labeling the time and site of each blood culture draw is crucial. If a blood culture drawn from a central line lumen turns positive ≥ 120 minutes before a peripherally drawn culture, it strongly suggests a catheter-related bloodstream infection (CRBSI) and may necessitate line removal.

3. Radiographic and Ancillary Studies

Imaging should be targeted to suspected sites of infection. However, given the muted inflammatory response in FN, a low threshold for advanced imaging is warranted to uncover occult infections.

A. Chest Imaging

A chest X-ray is indicated for any patient with respiratory symptoms or hypoxia. However, a high-resolution chest CT (HRCT) is far more sensitive for detecting early-stage bacterial or invasive fungal pneumonias, which may appear as subtle ground-glass opacities or nodules not visible on plain film.

B. Other Imaging Modalities

  • Ultrasonography: Useful for evaluating for deep-seated abscesses (e.g., hepatic, renal, perirectal) or septic thrombophlebitis.
  • MRI: The modality of choice for suspected central nervous system, spinal (e.g., epidural abscess), or bone infections.

C. Viral and Antigen Testing

During appropriate seasons or in outbreak settings, nasopharyngeal swabs for viral PCR panels (e.g., influenza, RSV, SARS-CoV-2) should be considered, as viral infections can mimic or co-exist with bacterial sepsis.

4. Risk Stratification Tools

Validated scoring systems are used to identify low-risk patients who may be candidates for outpatient management versus high-risk individuals requiring inpatient admission and intensive monitoring.

Comparison of Febrile Neutropenia Risk Scores
Risk Score Primary Population Low-Risk Definition
MASCC Risk Index Solid tumors and hematologic malignancies Score ≥ 21 (out of 26)
Talcott’s Rules All cancer patients Group IV (no comorbidities, controlled cancer)
CISNE Score Solid tumors only Score 0-2 (out of 8)

D. Absolute Exclusion Criteria for Outpatient Management

Even if a patient has a “low-risk” score, they are NOT a candidate for outpatient therapy if any of the following are present:

  • Hemodynamic instability (hypotension, tachycardia)
  • New-onset organ dysfunction (e.g., hypoxia, acute kidney injury)
  • Severe mucositis or uncontrolled diarrhea
  • Poor performance status (e.g., ECOG > 2)
  • Uncontrolled comorbidities or active neurologic changes
  • Known or suspected catheter-related infection
  • Unreliable patient or lack of adequate home support and transportation
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Scores Augment, Not Replace, Judgment

Risk scores are powerful tools, but they must be combined with clinical judgment. A patient with a MASCC score of 21 who lives alone two hours from the hospital is not a safe candidate for outpatient care. Always confirm the absence of exclusion criteria and ensure a robust plan for follow-up.

5. Decision Algorithms

The final disposition decision integrates objective risk scores, a thorough clinical assessment, and logistical factors to safely determine the appropriate site of care.

Febrile Neutropenia Management Algorithm A flowchart showing the decision-making process for a patient with febrile neutropenia. It starts with initial assessment, moves to risk stratification, then branches to either inpatient or outpatient management based on risk level and exclusion criteria, and ends with the need for daily reassessment. Patient Presents withFebrile Neutropenia (FN) Initial Assessment & Risk Stratification (MASCC, etc.) Risk Level? High Risk Inpatient Admission Low Risk Check for Exclusion Criteria & Social/Logistical Barriers Any Present? (Yes) None (No) Outpatient Management Daily Reassessment is Mandatory
Figure 1: FN Management Algorithm. This flowchart illustrates the critical pathway from initial presentation to disposition. High-risk patients or those with any exclusion criteria require inpatient admission. Low-risk patients without exclusions may be candidates for outpatient care, but all patients require close follow-up and daily reassessment.

A. Inpatient vs. Outpatient Criteria

  • Inpatient Admission: Required for all high-risk patients (e.g., MASCC < 21, CISNE ≥ 3) and any low-risk patient with one or more exclusion criteria.
  • Outpatient Candidacy: Reserved for patients who are low-risk by a validated score (e.g., MASCC ≥ 21), have no exclusion criteria, and have reliable home support with a clear plan for follow-up within 24-48 hours. The typical empiric oral regimen is a fluoroquinolone (e.g., ciprofloxacin or levofloxacin) plus amoxicillin/clavulanate.

B. Triggers for ICU Escalation

Any patient with FN who develops signs of severe sepsis or septic shock requires immediate escalation to an ICU setting. Key triggers include:

  • Persistent hypotension (SBP < 90 mm Hg or MAP < 65 mm Hg) despite fluid resuscitation.
  • Rising lactate > 2 mmol/L.
  • Acute change in mental status.
  • New or escalating oxygen requirement.

References

  1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2011;52:e56–e93.
  2. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: ASCO/IDSA guideline update. J Clin Oncol. 2018;36:1443–1453.
  3. Klastersky J, Paesmans M, Rubenstein EB, et al. The MASCC risk index: identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051.
  4. Talcott JA, Finberg R, Mayer RJ, Goldman L. Clinical identification of a low-risk subgroup in FN. Arch Intern Med. 1988;148:2561–2568.
  5. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Validation of the CISNE score. J Clin Oncol. 2015;33:465–471.
  6. Raad I, Hanna H, Alakech B, et al. Differential time to positivity for catheter-related bloodstream infections. Ann Intern Med. 2004;140:18–25.
  7. Hoeboer SH, van der Geest PJ, Nieboer D, et al. Diagnostic accuracy of procalcitonin for bacteremia: meta-analysis. Clin Microbiol Infect. 2015;21:474–481.
  8. Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in FN. BMC Health Serv Res. 2014;14:162.
  9. Rosa RG, Goldani LZ. Time to antibiotic administration and mortality in FN. Antimicrob Agents Chemother. 2014;58:3799–3803.